The DCPS Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte cell line, engineered for targeted disruption of the DCPS gene. This genetic perturbation creates a loss-of-function model that abolishes scavenger decapping enzyme activity, providing a powerful tool for dissecting the mechanisms of mRNA cap hydrolysis and RNA turnover in a lymphoid cellular context.
The Raji cell line, originating from a Burkitt??s lymphoma patient, serves as an immortalized B lymphocyte model widely employed in immunological and oncological research. These cells retain key features of humoral immunity and B-cell biology, including surface immunoglobulin expression and rapid proliferation, making them particularly relevant for investigating B-cell malignancies and the molecular pathways that govern lymphocyte function and transformation.
DCPS encodes the scavenger decapping enzyme that hydrolyzes the N7-methylguanosine (m7G) cap from short, capped oligonucleotides produced during 3??-to-5?? exonucleolytic decay. This activity is integral to the scavenger decapping pathway, where DCPS functions downstream of the exosome complex and acts in concert with the 5??-to-3?? exonuclease XRN1 to ensure complete mRNA degradation. DCPS interacts with components of the exosome complex and is situated within a broader mRNA decay network that includes DCP1/DCP2 and the Lsm1-7 complex, preventing buildup of capped fragments and maintaining RNA homeostasis.
In the Raji B lymphocyte background, disruption of DCPS allows researchers to explore the consequences of impaired mRNA turnover on gene expression programs essential for B-cell proliferation, survival, and malignant transformation. Given the association of DCPS mutations with Al-Raqad syndrome??a neurodevelopmental disorder??this knockout model also provides a context for understanding tissue-specific roles of mRNA decay. Moreover, in B-cell malignancies, aberrant mRNA metabolism can contribute to oncogenesis, making this model valuable for assessing the therapeutic potential of targeting RNA decay pathways.
Researchers can employ the DCPS Knockout Raji Polyclonal Cells in a wide range of applications, including mRNA stability assays using RT-qPCR and RNA sequencing to map transcriptome-wide changes, Western blotting and immunofluorescence to validate protein expression, and flow cytometry or apoptosis assays to evaluate functional outcomes. This model is also suited for drug sensitivity studies aimed at identifying vulnerabilities in lymphoma cells with defective decapping activity. For further information or to discuss how this product can advance your research, please contact Ascent Research.
